Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer

1998 ◽  
Vol 30 (1) ◽  
pp. 41-44 ◽  
Author(s):  
F. Yalçinkaya ◽  
L. Kamiş ◽  
O. Özteke ◽  
B. Günlüsoy ◽  
O. Yiĝitbasi ◽  
...  
Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S203
Author(s):  
K. Hammoud ◽  
M. Elsheikh ◽  
H. Abdelraouf ◽  
A. Aboumohamed ◽  
Y. Ramadan ◽  
...  

1996 ◽  
Vol 27 (S 1) ◽  
pp. 51-53
Author(s):  
H. Tanaka ◽  
J. Yoshimasa ◽  
Y. Furukawa ◽  
Y. Arai ◽  
T. Araki

1997 ◽  
Vol 25 (1) ◽  
pp. 31-34 ◽  
Author(s):  
E. C. de Boer ◽  
L. Somogyi ◽  
G. J. W. de Ruiter ◽  
Th. M. de Reijke ◽  
K. -H. Kurth ◽  
...  

1994 ◽  
Vol 22 (3) ◽  
pp. 177-184 ◽  
Author(s):  
M. J. J. G. Stassar ◽  
P. D. J. Vegt ◽  
P. A. Steerenberg ◽  
A. P. M. van der Meijden ◽  
H. D. Meiring ◽  
...  

2011 ◽  
Vol 22 (3) ◽  
pp. 104-106 ◽  
Author(s):  
Vitaly Golub ◽  
Prashant Malhotra ◽  
Shital Patel

Bacille Calmette-Guérin (BCG) immunotherapy is widely used for the treatment of superficial bladder cancer. The authors believe that the present report is one of the first to document cerebral BCG tuberculoma in a 73-year-old immunocompetent man, three years after intra-vesical BCG immunotherapy. His workup revealed no identifiable extracranial source. He responded well to treatment with rifampin, ethambutol and moxifloxacin.Patients undergoing intravesical BCG therapy should be closely monitored for the development of this complication. Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections.


1988 ◽  
Vol 139 (2) ◽  
pp. 410-414 ◽  
Author(s):  
Timothy L. Ratliff ◽  
Louis R. Kavoussi ◽  
William J. Catalona

Urology ◽  
1992 ◽  
Vol 40 (2) ◽  
pp. 175-179 ◽  
Author(s):  
Pierfrancesco Bassi ◽  
Claudio Milani ◽  
Agostino Meneghini ◽  
Antonio Garbeglio ◽  
Francesco Aragona ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document